Bulumtatug fuvedotin (9MW2821), a Nectin-4–targeting antibody-drug conjugate, showed promising activity in patients with recurrent or metastatic cervical cancer who had progressed after platinum-based chemotherapy..
In a phase 1/2 study of 53 patients, 73.6% experienced tumor shrinkage. The confirmed overall response rate was 32.08%, including one complete response and 16 partial responses. Disease control was achieved in 81.13% of patients, with a median duration of response of 5.98 months. Median progression-free survival was 3.9 months, and median overall survival reached 19.4 months. In patients previously treated with immunotherapy, the drug remained active, with a response rate of 29.03% and longer response duration of 9.10 months.
Side effects were common but generally manageable, mainly involving low blood counts such as leukopenia, anemia, and neutropenia. Although dose interruptions were frequent, few patients stopped treatment permanently. A phase 3 trial comparing the drug with chemotherapy is now underway.